Rena M Conti
Dados Biográficos
| ID | 1471109 |
|---|---|
| NOME | Rena M Conti |
| PRENOMES | Rena M |
| SOBRENOME | Conti |
| ASSINATURA | CONTI R M |
| AFILIAÇÕES | Boston University |
| ORCID | 0000-0002-4190-1839 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 11 |
| TOTAL DE CITAÇÕES | 4 |
| TOTAL COMO AUTOR | 11 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2012 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2025 |
| ÍNDICE H | 1 |
Cost-Sharing and Buprenorphine Prescription Dispensing
This cross-sectional study estimates the association between cost-sharing and buprenorphine dispensing among commercially insured and Medicare-insured patients
Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists
This Viewpoint discusses supply and demand for glucagon-like peptide 1 (GLP-1) receptor agonists and concerns with using compounded drugs to fill this demand
Mortality in the families of children during the Covid-19 pandemic
During the pandemic, the proportion of privately insured children experiencing the loss of an adult family members varied over time, with the highest rates occurring at the end of 2020 and the second half of 2021. Some children lost adult siblings, suggesting that screening for child bereavement should include all family members, not just parents/guardians
The Economics of Generic Drug Shortages
We examine the economics of the US generic prescription drug market, which comprises the majority of medicines sold. The market is celebrated for its benefits in the form of high quality and low prices for consumers but is also increasingly challenged by shortages that may disrupt patient care. Shortages in the generic drug market present an economic puzzle — in the face of a shortage, prices should rise, encouraging entry, yet we observe shortag…
How Do Commercial Insurance Plans Fare Under Proposed Prescription Drug Price Regulation
The 2 leading current proposals to control prescription drug pricing in the US, H.R. 3 and H
Projections of US Prescription Drug Spending and Key Policy Implications
Response to Joyce and Sood
The Advantages of Awarding the Federal Government Negotiating Power Over the Prices of Prescription Drugs
Pricing in the Market for Anticancer Drugs
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab-brand name Yervoy-at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the launch prices of new anticancer drugs and other drugs in the so-called "specialty" pharmaceutical market have been increasing over time and that increases are…
The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs
BACKGROUND: Spending on physician-administered drugs is high and uses not approved by the US Food and Drug Administration (FDA) are frequent. Although these drugs may be targets of future policy efforts to rationalize use, little is known regarding how physicians respond to emerging safety and effectiveness evidence. STUDY OBJECTIVE: We analyzed changes in bevacizumab (Avastin) use for breast cancer in response to its market launch (February 2008…
Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors
OBJECTIVE: To review literature on the impact of The Food and Drug Administration (FDA) drug risk communications on medication utilization, health care services use, and health outcomes. DATA SOURCES: The authors searched MEDLINE and the Web of Science for manuscripts published between January 1990 and November 2010 that included terms related to drug utilization, the FDA, and advisories or warnings. We manually searched bibliographies and works …
Pricing in the Market for Anticancer Drugs
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab-brand name Yervoy-at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the launch prices of new anticancer drugs and other drugs in the so-called "specialty" pharmaceutical market have been increasing over time and that increases are…
Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors
OBJECTIVE: To review literature on the impact of The Food and Drug Administration (FDA) drug risk communications on medication utilization, health care services use, and health outcomes. DATA SOURCES: The authors searched MEDLINE and the Web of Science for manuscripts published between January 1990 and November 2010 that included terms related to drug utilization, the FDA, and advisories or warnings. We manually searched bibliographies and works …
The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs
BACKGROUND: Spending on physician-administered drugs is high and uses not approved by the US Food and Drug Administration (FDA) are frequent. Although these drugs may be targets of future policy efforts to rationalize use, little is known regarding how physicians respond to emerging safety and effectiveness evidence. STUDY OBJECTIVE: We analyzed changes in bevacizumab (Avastin) use for breast cancer in response to its market launch (February 2008…
Pricing in the Market for Anticancer Drugs
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab-brand name Yervoy-at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the launch prices of new anticancer drugs and other drugs in the so-called "specialty" pharmaceutical market have been increasing over time and that increases are…
Response to Joyce and Sood
The Advantages of Awarding the Federal Government Negotiating Power Over the Prices of Prescription Drugs
How Do Commercial Insurance Plans Fare Under Proposed Prescription Drug Price Regulation
The 2 leading current proposals to control prescription drug pricing in the US, H.R. 3 and H
Projections of US Prescription Drug Spending and Key Policy Implications
Cost-Sharing and Buprenorphine Prescription Dispensing
This cross-sectional study estimates the association between cost-sharing and buprenorphine dispensing among commercially insured and Medicare-insured patients
Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists
This Viewpoint discusses supply and demand for glucagon-like peptide 1 (GLP-1) receptor agonists and concerns with using compounded drugs to fill this demand
Mortality in the families of children during the Covid-19 pandemic
During the pandemic, the proportion of privately insured children experiencing the loss of an adult family members varied over time, with the highest rates occurring at the end of 2020 and the second half of 2021. Some children lost adult siblings, suggesting that screening for child bereavement should include all family members, not just parents/guardians
The Economics of Generic Drug Shortages
We examine the economics of the US generic prescription drug market, which comprises the majority of medicines sold. The market is celebrated for its benefits in the form of high quality and low prices for consumers but is also increasingly challenged by shortages that may disrupt patient care. Shortages in the generic drug market present an economic puzzle — in the face of a shortage, prices should rise, encouraging entry, yet we observe shortag…
Medicine (10 obras) · Pharmaceutical Economics and Policy (6 obras) · Health Systems, Economic Evaluations, Quality of Life (5 obras) · Internal Medicine (5 obras) · Pharmacology (5 obras) · Business (4 obras) · Medical prescription (4 obras) · Computer Science (3 obras) · Drug (3 obras) · Economic and Financial Impacts of Cancer (3 obras)